NCT04744207已完成2 期
A Phase II, Randomized, Multi-center, Placebo-controlled, Double-blind Study to Investigate the Safety of GS-248, and Efficacy on Raynaud's Phenomenon (RP) and Peripheral Vascular Blood Flow, in Subjects With Systemic Sclerosis (SSc)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 94
- 试验地点
- 2
- 主要终点
- Mean Change From Baseline to Week 4 in the Number of Raynaud Attacks Per Week.
研究概览
简要总结
The primary objective of this study is to determine the safety, and evaluate the efficacy of GS-248 versus placebo on Raynaud's Phenomenon (RP) in subjects with Systemic Sclerosis (SSc).
详细描述
The primary objective of this study is to determine the safety, and evaluate the efficacy of GS-248 versus placebo on Raynaud's Phenomenon (RP) in subjects with Systemic Sclerosis (SSc).
This is a randomized, double-blind, placebo-controlled study conducted in multiple sites in 4 countries in Europe. Approximately 80 subjects will be randomized in a 1:1 allocation to receive either GS-248 (120 mg) or placebo once daily. The study will comprise an enrolment period, a treatment period, and a follow-up period, with a total of 5 study visits over approximately 10 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must provide signed and dated written informed consent before the conduct of any study-specific procedures.
- •Male and female subjects aged 18-75 years inclusive.
- •Systemic Sclerosis diagnosed according to European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) criteria (van den Hoogen F et al. 2013). Subjects with signs of other autoimmune diseases (e.g. Sjögren's syndrome, myositis, rheumatoid arthritis) could be included if SSc is the dominating phenotype.
- •Raynaud attacks typically ≥7 times per week during the last 4 weeks prior to screening despite background medication (only allowed vasodilatory therapy is calcium channel blockers or PDE-5 inhibitors).
- •Women of childbearing potential must be using a highly effective method of contraception to avoid pregnancy throughout the study and for 4 weeks after the last dose of Investigational Medicinal Product in such manner that the risk of pregnancy is minimised.
- •Women must not be pregnant or breastfeeding.
- •Male subjects to agree to use condom in combination with use of contraceptive methods with a failure rate of <1% to prevent pregnancy and drug exposure of a partner, and refrain from donating sperm from the first date of dosing until 3 months after last dosing of the IMP.
- •Ability of subjects to participate fully in all aspects of this clinical trial.
排除标准
- •Systemic Sclerosis disease duration of greater than 120 months from first non-Raynaud manifestation
- •Current smokers or stopped smoking <3 months prior to Visit
- •Dose-change or initiation of vasodilating substances (calcium blockers or PDE-5 inhibitors) within 4 weeks prior to Visit
- •Use of iloprost or other intravenous (iv) or po prostacyclin receptor agonist within 4 weeks prior to Visit
- •Ongoing treatment with immunosuppressive therapies (other than mycophenolate) including, but not restricted to; cyclophosphamide, azathioprine, methotrexate, or cyclosporine, or use of those medications within 4 weeks of trial entry.
- •Use of systemic corticosteroids during 4 weeks before screening and during the course of the study.
- •Concurrent serious medical condition, with special attention to cardiovascular conditions, which in the opinion of the Investigator makes the subject not suitable for this study.
- •Prolonged QTcF interval defined as a mean QTcF >450 msec.
- •Creatinine clearance <50 mL/min (determined by Cockcroft-Gault equation) at Screening.
- •Active digital ulcer (DU) within 4 weeks prior to Visit
- •Clinically meaningful laboratory abnormalities at Screening (Visit 1), as determined and documented by the Investigator.
研究组 & 干预措施
GS-248
Experimental
GS-248, capsule, 120 mg, once daily for 4 weeks
干预措施: GS-248 (Drug)
Placebo
Placebo Comparator
placebo, capsule, once daily for 4 weeks
干预措施: Placebo (Drug)
结局指标
主要结局
Mean Change From Baseline to Week 4 in the Number of Raynaud Attacks Per Week.
时间窗: From baseline to week 4, i.e. the 7 most recent days prior to Visit 2 and Visit 4 respectively
Patient reported number of Raynaud's attacks per day as registered in electronic diary.
次要结局
- Mean Change From Baseline to Week 4 in the Raynaud's Condition Score.(From baseline to week 4, i.e. the 7 most recent days prior to Visit 2 and Visit 4 respectively)
- Mean Change From Baseline to Week 4 in Pain Experienced During Raynaud Attacks.(From baseline to week 4, i.e. the 7 most recent days prior to Visit 2 and Visit 4 respectively)
- Mean Change From Baseline to Week 4 in the Mean Duration of Raynaud's Attacks(From baseline to week 4, i.e. the 7 most recent days prior to Visit 2 and Visit 4 respectively)
- Mean Change From Baseline to Week 4 in the Cumulative Duration of Raynaud Attacks.(From baseline to week 4, i.e. the 7 most recent days prior to Visit 2 and Visit 4 respectively)
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
Study of GS-0272 in Participants With Rheumatoid ArthritisRheumatoid ArthritisNCT06031415Gilead Sciences55
已完成
2 期
SU011248 for Platinum-Refractory Urothelial Cancer Evaluation TrialUrothelial CancerAdultBladder CancerNCT00578526AHS Cancer Control Alberta64
已完成
1 期
A Study to Investigate the Safety of GSK4024484 in Healthy Adult ParticipantsMalaria, FalciparumNCT06171113GlaxoSmithKline123
撤回
2 期
Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) TreatmentRheumatoid ArthritisNCT05165771Gilead Sciences
已完成
2 期
Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With MethotrexateRheumatoid ArthritisNCT02885181Gilead Sciences83